SPONSOR
Fujian Shengdi Pharmaceutical Co., Ltd.
Total Trials
5
Recruiting
5
Phases
Phase 2, Phase 3, Phase 1
Conditions studied: Chronic Hepatitis BBstructive Sleep Apnea (OSA) and ObesityReversal of Neuromuscular BlockadeSubjects With Mild HypertensionOverweight or Obesity
NCT06425341 Phase 2
Recruiting
A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B
Chronic Hepatitis B
NCT06974851 Phase 3
Recruiting
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
Bstructive Sleep Apnea (OSA) and Obesity
NCT07195604 Phase 1
Recruiting
A Single Ascending Dose of HRS-2162 in Healthy Subjects
Reversal of Neuromuscular Blockade
NCT07117474 Phase 1
Recruiting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.
Subjects With Mild Hypertension
NCT07150962 Phase 1
Recruiting
Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects
Overweight or Obesity